Adicet Bio, Inc.

As of May 9, 2023, Adicet Bio, Inc. is considered overvalued with a valuation grade of "does not qualify," reflecting poor financial metrics such as a -72.67% return on equity and a year-to-date stock performance of -34.01%, significantly underperforming its peers and the S&P 500.

As of June 13, 2025, the technical trend is mildly bearish due to bearish daily moving averages and Bollinger Bands, despite some mixed signals from the MACD and KST.

As of March 2022, the management team of Adicet Bio, Inc. is led by Mr. Chen Schor as President and CEO, with a Board of Directors that includes Mr. Erez Chimovits, Mr. Steve Dubin, Mr. Carl Gordon, Dr. Aya Jakobovits, and Dr. Bastiano Sanna.

Adicet Bio, Inc. is a biotechnology company developing allogeneic gamma delta T cell therapies for cancer and other diseases, classified as a micro-cap with a market cap of $55.61 million. As of March 2025, it reported a net profit loss of $28 million and has no dividend yield.

As of Jun 18, Adicet Bio, Inc. has a market capitalization of 55.61 million and reported net sales of 0.00 million, with a net profit of -117.32 million over the latest four quarters. Shareholder's funds are 186.61 million, and total assets amount to 220.22 million.